UPDATE : Friday, October 18, 2019
상단여백
Medytox exported ₩3.3 billion worth of unqualified BTX
The Ministry of Food and Drug Safety ordered Medytox to recall and discard ...
by Jeong Sae-im  |  2019-10-18 16:02
라인
State organs squandered ₩8.2 billion; failed to spot Invossa problem
The government invested 8.21 billion won ($6.9 million) in healthcare-relat...
by Kwak Sung-sun  |  2019-10-16 15:06
라인
[Exclusive] Samsung admits it failed to develop Rituxan biosimilar
The Samsung Group has admitted that a Samsung-affiliated company failed to ...
by Jeong Sae-im  |  2019-10-16 14:16
라인
Kolon Life Science shares surge after TissueGene’s survival
Shares of Kolon Life Science shot up after the regulator decided to delay t...
by Jeong Sae-im  |  2019-10-14 18:01
라인
HLB merges with Elevar to own rivoceranib rights
HLB said it would merge with its subsidiary Elevar, a U.S.-based developer ...
by Jeong Sae-im  |  2019-10-14 14:43
라인
Samsung Bioepis to present data of Etanercept biosimilar in Europe
Samsung Bioepis said that it has unveiled the real-world data (RWD) of Bene...
by Lee Han-soo  |  2019-10-10 11:31
라인
‘Kosdaq firms listed for exceptional tech need special monitoring’
About 80 percent of companies listed on the Kosdaq stock market using the r...
by Jeong Sae-im  |  2019-10-07 15:51
라인
SK Plasma launches human immunoglobulin in Brazil
SK Plasma said that it has won the $20-million bid to supply LIV-Gamma, a h...
by Lee Han-soo  |  2019-10-07 11:23
라인
‘New law to support advanced biopharmaceuticals, ensure safety’
The Ministry of Food and Drug Safety is preparing to implement the “Act on ...
by Lee Hye-seon  |  2019-10-04 15:18
라인
Samsung execs pass buck to biotech subsidiaries for destroying evidence
Samsung executives said Samsung BioLogics and Samsung Bioepis workers were ...
by Jeong Sae-im  |  2019-10-04 11:42
라인
Samsung Bioepis releases P3 results of Bevacizumab biosimilar in EU
Samsung Bioepis has presented the results of phase 3 study clinical evaluat...
by Lee Han-soo  |  2019-09-27 11:37
라인
‘Samsung BioLogics destroyed evidence to hide accounting fraud for months’
Executives of Samsung BioLogics and affiliated companies claimed that they ...
by Jeong Sae-im  |  2019-09-26 15:24
라인
Celltrion to start marketing Herzuma in Middle East
Celltrion Healthcare said that it won the bid to sell Herzuma, an anticance...
by Lee Han-soo  |  2019-09-26 15:02
라인
Helixmith blames hospital for absurd drug mix-up
Helixmith used to be one of the promising biotech firms with its market cap...
by Jeong Sae-im  |  2019-09-25 13:42
라인
Court rejects Kolon’s appeal over Invossa license revocation
A Seoul court turned down Kolon Life Science’s appeal for stopping the gove...
by Jeong Sae-im  |  2019-09-25 11:18
라인
FDA recommends Kolon to remanufacture Invossa’s second fluid
The U.S. Food and Drug Administration has recommended Kolon TissueGene to r...
by Jeong Sae-im  |  2019-09-23 15:32
라인
Dong-A ST's Aranesp biosimilar gets nod in Japan
Dong-A ST said that Sanwa Kagaku Kenkyusho (SKK), its Japanese partner, has...
by Lee Han-soo  |  2019-09-23 15:31
라인
Biotech startups seek IPO via ‘growth potential exception’ policy
An increasing number of biotech companies are eyeing on the Korea Exchange’...
by Jeong Sae-im  |  2019-09-17 11:26
라인
Top court rejects financial regulator’s retry to discipline Samsung BioLogics
The Financial Services Commission (FSC)'s disciplinary action against S...
by Jeong Sae-im  |  2019-09-10 14:36
라인
Canada OKs Celltrion's biosimilar
Celltrion said that Health Canada has given the go-ahead for Herzuma (Ingre...
by Lee Han-soo  |  2019-09-10 12:48
여백
여백
여백
Back to Top